Log In

Status Information

Status
TRIAL

Term Description

The predicted risk of an adverse drug reaction based on the variant(s) detected. For example, a patient who is HLA-B*57:01 positive has a significant risk of abacavir hypersensitivity reactions (HSR). For individuals taking pazopanib and found to be HLA-B*57:01 carriers, they have an increased risk of elevated alanine aminotransferase (ALT) levels when taking pazopanib.

LOINC Names Get Info

Fully-Specified Name
Risk of adverse drug reaction sequence variation interpretation:Imp:Pt:Bld/Tiss:Nar:
Long Common Name
Genetic variation's effect on risk of adverse drug reaction
Short Name
Adverse drug seq var interp Bld/T-Imp
Display Name
Risk of adverse drug reaction sequence variation interpretation Nar (Bld/Tiss) [Interp]
Consumer Name Alpha Get Info
Risk of adverse drug reaction sequence variation interpretation, Blood or tissue specimen

Part Model Get Info

  • Component
    Risk of adverse drug reaction sequence variation interpretation
    LP411431-2
    • Analyte
      Risk of adverse drug reaction sequence variation interpretation
      LP411431-2
      • Component Numerator
        Risk of adverse drug reaction sequence variation interpretation
        LP411431-2
        • Component Numerator Core
          Risk of adverse drug reaction sequence variation interpretation
          LP411431-2
        • Component Numerator Core Suffix
          NULL
           
      • Component Denominator
        NULL
         
        • Component Denominator Core
          NULL
           
        • Component Denominator Core Suffix
          NULL
           
    • Challenge
      NULL
       
    • Adjustment
      NULL
       
    • Count
      NULL
       
  • Property
    Imp
    LP6819-9
  • Time
    Pt
    LP6960-1
  • System
    Bld/Tiss
    LP7061-7
    • System Core
      Bld/Tiss
      LP7061-7
    • Super System
      NULL
       
  • Scale
    Nar
    LP7749-7
  • Method
    NULL
     

Basic Attributes

Class
MOLPATH.PHARMG
Type
Laboratory
First Released
Version 2.67
Last Updated
Version 2.67 (ADD)
Order vs. Observation
Observation

Member of these Panels

LOINCLong Common Name
94855-4carBAMazepine hypersensitivity genotype panel - Blood or Tissue

Language Variants Get Info

TagLanguageTranslation
cs-CZCzech (Czechia)Riziko nežádoucího účinku léčiva interpretace sekvenční varianty:Interpretace:Časový bod:Krev/tkáň:Narativní:
el-GRGreek (Greece)Κίνδυνος ερμηνείας παραλλαγής αλληλουχίας ανεπιθύμητης ενέργειας φαρμάκου:Imp:Pt:Αίμα/Ιστός:Nar:
Synonyms: Imp MOLPATH MOLPATH.PHARMG Nar Pt Αίμα Αίμα/Ιστός Ανεπιθύμητη ενέργεια φαρμάκου Ερμηνεία Ιστός Κίνδυνος ερμηνείας παραλλαγής αλληλουχίας ανεπιθύμητης ενέργειας φαρμάκου Φάρμακο
es-ESSpanish (Spain)Riesgo de interpretación de variación de secuencia de reacción adversa al fármaco:Impresión/interpretación del estudio:Punto temporal:Sangre o tejido:Narrativo:
es-MXSpanish (Mexico)Riesgo de interpretación de la variación de la secuencia de reacciones adversas al fármaco:Impresión / interpretación del estudio:Punto temporal:Sangre o tejido:Narrativo:
fr-FRFrench (France)Risque de variation de la séquence des effets indésirables d'un médicament interprétation:Interprétation:Ponctuel:Sang/Tissu:Résultat textuel:
it-ITItalian (Italy)Rischio di interpretazione della variazione della sequenza di reazione avversa al farmaco:Imp:Pt:Sangue/Tess:Nar:
Synonyms: Farmacogenomica Impressione/interpretazione di studio Patologia molecolare Punto nel tempo (episodio) Sangue Sangue o Tessuto Tessuto & Strisci
zh-CNChinese (China)药物不良反应序列变异风险解释:印象:时间点:全血/组织:叙述型:
Synonyms: React Rxn 不良药物反应史 全血或组织;血液/组织;血液或组织 分子病理学;分子病理学试验 判读;解释说明;说明;释义;阐明 印象是一种诊断陈述，始终是对其他某种观察指标的解释或抽象（一系列检验项目结果、一幅图像或者整个某位病人），而且几乎总是由某位专业人员产生。;检查印象;检查印象/解释;检查的印象/解释;检查解释;解释;阐释 叙述;叙述性文字;报告;报告型;文字叙述;文本叙述型;文本描述;文本描述型 响应 时刻;随机;随意;瞬间 未作说明的组织;组织;组织 & 涂片 毒品 毒品;麻醉药;麻醉品;麻药;兴奋剂;药品 毒品类 药品类 药物 药物类 血;血液

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=93308-5